Silodosin (Sild) is a selective α1A-adrenergic receptor antagonist effective in treating benign prostatic hyperplasia (BPH), a condition characterized by prostate enlargement, which leads to urinary dysfunction.
Objective:
This study aimed to radiolabel Sild with iodine-131 [131I]) using chloramine-T(Ch-T), optimized the process to achieve high radiochemical yields, and investigated the [131I]Sildodosin [131I]Sild) radiotracer in the prostate of murine models.
Methods:
Compared to a control group, biodistribution studies were conducted to evaluate the [131I]Sild radiotracer uptake in mice with BPH. Biochemical analyses were performed to assess serum prostate-specific antigen (PSA) levels, antioxidant enzyme activities catalase (CAT) and superoxide dismutase (SOD), and oxidative stress markers such as malondialdehyde (MDA) in both groups.
Results:
The [131I]Sild radiotracer exhibited a radiochemical yield of 93.7 ± 1.1% and maintained stability for up to 4 h in serum. Biochemical markers indicated an increase in PSA, lipid peroxidation, MDA levels, and protein content, with an increase in prostate weight in mice with BPH compared to the control group. Histopathological examination revealed disruption of tissue growth and a localized inflammatory response in BPH compared to the control. Biodistribution studies demonstrated significant uptake of the [131I]Silodosin radiotracer in BPH, with a value of 7.6 ± 0.18% ID/g at 120 min post-administration.
Conclusion:
The results suggest that [131I]Silodosin radiotracer holds potential as an imaging agent for chronic prostatic diseases, particularly BPH.
Get full access to this article
View all access options for this article.
References
1.
LaunerBM, McVaryKT, RickeWA, et al.The rising worldwide impact of benign prostatic hyperplasia. BJU Int, 2021; 127(6):722–728.
2.
Ontario Health. Prostatic artery embolization for benign prostatic hyperplasia: A health technology assessment. Ont Health Technol Assess Ser, 2021; 21(6):1–139.
3.
HataJ, HariganeY, MatsuokaK, et al.mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia. Int J Mol Sci, 2023; 24(14):11634.
4.
The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study. Lancet Healthy Longev, 2022; 3(11):e754–e776.
5.
AwedewAF, HanH, AbbasiB, et al.The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity, 2022; 3(11):e754–e776.
6.
TaokaR, KakehiY. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic Hyperplasia. Asian J Urol, 2017; 4(3):158–163.
7.
KramerG, MittereggerD, MarbergerM. Is benign prostatic hyperplasia (BPH) an Immune inflammatory disease? Eur Urol, 2007; 51(5):1202–1216.
8.
OseniSO, NaarC, PavlovićM, et al.The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: Prostatitis, benign prostatic hyperplasia, and prostate Cancer. Cancers (Basel), 2023; 15(12):3110.
9.
XuZ, ChenX, ZhouH, et al.An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate. Front Endocrinol (Lausanne), 2024; 15:1335146–1335146.
ShinBNH, QuL, TanSX, et al.“Google infodemiology and temporal trends in benign prostatic hyperplasia surgery in Australia. BJU Int, 2025.
12.
AnS, YangH, MengQ. “Effect of ERAS-Based Rapid Bladder Irrigation on TURP and HoLEP in the Treatment of Benign Prostatic Hyperplasia. Pakistan Journal of Medical Sciences , 2025; 41(3):693–698.
13.
Valdivia y AlvaradoM, et al.“The evolving landscape of BPH surgical treatments: Considering semen parameters in clinical decision-making. Prostate Cancer and Prostatic Diseases, 2025:1–4.
14.
JindanL, XiaoW, and, LipingX. Evolving role of silodosin for the treatment of urological disorders–A narrative review. Drug Des Devel Ther, 2022; 16:2861–2884.
15.
ChoHJ, and, YooTK. Silodosin for the treatment of clinical benign prostatic hyperplasia: Safety, efficacy, and patient acceptability. Res Rep Urol, 2014; 6:113–119.
16.
MotaweaAM, et al.Effect of silodosin versus tamsulosin in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. The Egyptian Journal of Hospital Medicine, 2025 ;98:201–206.
17.
RajputHS, ShahN, MehtaK, et al.Alpha blockers in the management of acute urinary retention in prostatomegaly: A prospective observational study. Egyptian Pharmaceutical Journal, 2025; 24(1):17–28.
18.
RanjanKR, Singh andDP, SarkarD. Comparison of dual-agent alpha-blocker treatment with single agent in management of refractory lower urinary tract symptoms. Urological Science, 2025:10–1097.
19.
SeeversRH, and, CounsellRE. Radioiodination techniques for small organic molecules. Chem Rev, 1982 ;82(6):575–590.
20.
FarzinL, SheibaniS, MoassesiME, et al.An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions. J Biomed Mater Res A, 2019; 107(1):251–285.
21.
RefayeMSE, KhaterSI, EssamHM, et al.Radiosynthesis, in vitro and in vivo Evaluation of 99mTc-Silodosin as a Tumor Marker in Mice. Radiochemistry, 2021; 63(6):828–834.
22.
SanadMH, ChallanSB, EssamHM, et al.Design of a novel complex 99mTc-Nilutamide as a tracer for prostate cancer disorder detection in mice. Radiochimica Acta, 2025; 113(3):213–228. https://doi.org/10.1515/ract-2024-0303
23.
Linkows Ki FaintuchB, TeodoroR, DuattiA, et al.Radiolabeled bombesin analogs for prostate cancer diagnosis: Preclinical studies. Nucl Med Biol, 2008; 35(4):401–411.
24.
AminAM, EL-GhanyEA, MoustafaD. Iodine-125 nilutamide as novel radio-therapeutic Ligand for androgen receptor in prostate cancer. Arab Journal of Nuclear Science and Applications, 2009; 42(3):13–22.
25.
Afshar-OromiehA, ZechmannCM, MalcherA, et al.Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-Choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 2014; 41(1):11–20.
26.
KairemoK, JoensuuT. Lu-177 PSMA treatment for metastatic prostate cancer: Case examples of major responses. Clin Transl Imaging, 2018; 6(3):223–237.
27.
YamanME, AkmanTÇ. Optimization of HPLC-FLD conditions using analytical quality by design approach for quantification of silodosin in pharmaceutical dosage form. Erzincan University Journal of Science and Technology , 2021; 14(3):993–1005.
28.
AjiboyeBO, FatokiTH, AkinolaOG, et al.In silico exploration of anti-prostate cancer compounds from differential expressed genes. BMC Urol, 2024; 24(1):138.
29.
Long GuoQ, Long DingZ, IuWu. Effect of Baicalein on Experimental Prostatic Hyperplasia in Rats and Mice. Biol Pharm Bull, 2004; 27(3):333–337.
30.
SorokinaIV, ZhukovaNA, MeshkovaYV, et al.Modeling of benign prostatic hyperplasia in rats with a high dose of testosterone. Bull Exp Biol Med, 2022; 173(5):663–665.
31.
ZhangJ, ZhangM, TangJ, et al.Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 2021; 24(1):49–57.
32.
ChallanSB, MarzookFA, MassoudA. Synthesis of Radioiodinated Carnosine for Hepatotoxicity Imaging Induced by Carbon Tetrachloride and Its Biological Assessment in Rats. Radiochim Acta, 2020; 108(5):397–408; doi: 10.1515/ract-2019
33.
SanadM, ChallanS. Radioiodination and biological evaluation of rabeprazole as a peptic ulcer localization radiotracer. Radiochemistry, 2017; 59(3):307–312.
34.
SanadMH, MarzookEA, ChallanSB. Radioiodination of olmesartan medoxomil and biological evaluation of the product as a tracer for cardiac imaging. Radiochimica Acta, 2018; 106(4):329–336.
35.
SanadMH, ChallanSB, MarzookFA, et al.Radioiodination and biological evaluation of cimetidine as a new highly selective radiotracer for peptic ulcer disorder detection. RadiochimicaActa, 2021; 109(2):109–117.
36.
BoltiaSA, AbdelkawyM, MohamedTA, et al.Validated chromatographic and spectrofluorimetric methods for analysis of silodosin: A comparative study with application of RP-HPLC in the kinetic investigation of silodosin degradation. J AOAC Int, 2020; 103(4):946–957.
37.
SanadMH, MarzookFA, RizviSF, et al.Radioiodinated azilsartan as a new highly selective radiotracer for myocardial perfusion imaging. Radiochemistry , 2021; 63(4):520–525.
38.
SanadMH, EyssaHM, ChallanSB, et al.Facile one-pot strategy for brain imaging using radiolabeled [99mTc]-tricarbonyl histamine complex in Mice. Egyptian Journal of Chemistry., 2024; 68(3):37–50.
39.
SanadMH, Abdel RahimEA, RashedMM, et al.Radioiodination and biological evaluation of parathion as a new radiotracer to study in experimental mice. World Journal of Pharmacy and Pharmaceutical Sciences, 2020; 9(8):148–158.
40.
SanadMH, MarzookFA, ChallanSB, et al.Radioiodination, and biological assessment of olsalazine, as a highly selective radiotracer for ulcerative colitis imaging in mice. Arab J Nucl Sci & Applic, 2023; 0(0):0–0.
41.
MassoudA, ChallanSB, MaziadN. Characterization of polyvinyl pyrrolidone (PVP) with technetium-99m and its accumulation in mice. Journal of Macromolecular Science. Part A. Pure and Applied Chemistry, 2021; 58(6):408–418; doi: 10.1080/10601325.2021.1873070
42.
AliD, and, AhmedM. Prostatic estimation of time passed since death; oxidative stress markers, histological and immunohistochemical examination (an experimental study). Ain Shams Journal of Forensic Medicine and Clinical Toxicology, 2023 ;40(1):22–31.
43.
OBisikeUA, NwachukuEO, BoisaN, et al.Determination of exogenous testosterone propionate dose for induction of benign prostatic hyperplasia in rat model. European Journal of Biomedical and Pharmaceutical Sciences, 2019; 6(13):141–147.
44.
HugoA. Catalase in vitro. Methods in Enzymology, 1984; 105:121–126.
45.
ClaiborneA. Catalase activity in: Greenwald RA (ed) CRC handbook of methods in oxygen radical research. CRC Press.: Boca Raton: 1985; 8: 283–184.
46.
BergmeyerHU. Catalase. In: Methods of enzymatic analysis.(BergmeyerH. U., ed.) Vol. 2. New York: Academic Press; 1974:673–683.
47.
KelloggEWIII, FridovichI. Superoxide dismutase in the rat and mouse as a function of age and longevity. J Gerontol, 1976; 31(4):405–408.
48.
Mc CordJM, FridovichI. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem, 1969; 244(22):6049–6055.
49.
RaelLT, GregoryW, ThomasML, et al.Lipid Peroxidation and the Thiobarbituric Acid Assay: Standardization of the Assay When Using Saturated and Unsaturated Fatty Acids. Journal of Biochemistry and Molecular Biology, 2024; 37(6):749–752.
50.
OhkawaH, OhishiN, YagiK. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 1979; 95(2):351–358.
51.
LowryOH, RosebroughNJ, FarrAL, et al.Protein measurement with the Folin phenol reagent. J Biol Chem, 1951; 193(1):265–275.
52.
LateefA, RehmanMU, TahirM, et al.Farnesol protects against intratracheally instilled cigarette smoke Extract-induced histological alteration and oxidative stress in the prostate of Wistar rats. Toxicol Int, 2013; 20(1):35–42.
53.
ChallanSB, KhaterSI, RashadAM. Preparation, molecular modeling and in-vivo evaluation of 99mTc-Oseltamivir as a tumor diagnostic agent. Int J Radiat Res, 2022; 20(3):635–642.
54.
HussienH, KhaterSI, RashadAM. Experimental and computational study of rafoxanide radioiodination via isotopic exchange reaction. RadiochimicaActa, 2022; 110(4):259–265.
55.
SanadMH, MarzookFA, SalehGM, et al.Radiolabeling, preparation, and bioevaluation of 99mTc-azathioprine as a potential targeting agent for solid tumor imaging. Radiochemistry, 2019; 61(4):478–482.
56.
IbrahimIT, AbdelhalimSM, SanadMH, et al.Radioiodination of 3-Amino-2-quinoxalinecarbonitrile 1, 4-Dioxide and its biological distribution in erhlich ascites cancer bearing mice as a preclinical tumor imaging agent. Radiochemistry, 2017; 59(3):301–306.
57.
SanadMH, EyssaHM, MarzookFA, et al.Radiocomplexation, Biological Evaluation, and Characterization of [99mTc]-5-[(3-Carboxy-4-hydroxyphenyl) diazenyl]-2-hydroxybenzoic Acid as a Novel Agent for Imaging of Ulcerative Colitis in Mice. Radiochemistry, 2023; 65(3):378–386.
58.
MarzookEA, TalaatHM, ChallanSB. Comparative Biological Evaluation of 99mTc-Timonacic Acid Prepared Using Different Reducing Agents as a Complex for Hepatobiliary Imaging. Journal of. Radiochemistry, 2018; 60(3):309–315.
59.
SanadMH, RizviSF, FaragAB. Radiosynthesis and in silico bioevaluation of 131I-Sulfasalazine as a highly selective radiotracer for imaging of ulcerative colitis. Chem Biol Drug Des, 2021; 98(5):751–761.
60.
SanadMH, GomaaNM, El BakaryNM, et al.Radioiodination of balsalazide, bioevaluation, and characterization as a highly selective radiotracer for imaging of ulcerative colitis in mice. J Labelled Comp Radiopharm, 2022; 65(3):71–82.
61.
SanadMH, MarzookFA, IbrahimIT, et al.Preparation and bioevaluation of radioiodinated omberacetam as a radiotracer for brain imaging. Radiochemistry, 2023; 65(1):114–121.
62.
SanadMH. Facile One-Pot Strategy for Radiocoplexation of [99mtc]-Nitrido-Nebracetam for Brain Imaging: Biological Evaluation, Optimized Chromatographic Separation and Labeling Conditions. Egyptian Journal of Chemistry , 2024; 67(13):471–480; doi: 10.2160/8/ejchem.2024.257759.9053
63.
SanadMH, FouzyAS M, SobhyHM, et al.Tracing the protective activity of Lactobacillus plantarum using technetium-99m-labeled zearalenone for organ toxicity. Int J Radiat Biol, 2018; 94(12):1151–1158.
64.
SanadMH, GomaaNM, El Bakary, et al.Radioiodination and Biological Evaluation of Novel Quinoline Derivative for Infective Inflammation Diagnosis. Pharmaceutical Chemistry Journal, 2023; 57(7):1018–1028; doi: 10.1007/s11094-023-02979-x
65.
SanadMH, RizviFA, KumarRR. Radiosynthesis and bioevaluation of ranitidine as highly selective radiotracer for peptic ulcer disorder detection. Radiochemistry, 2020; 62(1):119–124.
66.
MotalebMA, El TawoosyM, MohamedSB, et al.99mTc-Labeled Teicoplanin and its Biological Evaluation in Experimental Animals for Detection of Bacterial Infection. Journal of. Radiochemistry, 2014; 56(5):544–549.
67.
BekheetS, TawoosyME, MassoudAA, et al.99mTc-Labeled Ceftazidime and Biological Evaluation in Experimental Animals for Detection of Bacterial Infection. American Journal of Biochemistry, 2014; 4(2):15–24.
68.
El-SharawyDM, KhaterSI, SherifNH, et al.99mTc-Luteolin: Radiolabeling, in silico ADMET and biological evaluation as a natural tracer tumor imaging. Journal of Radiation Research and Applied Sciences, 2021; 14(1):125–132.
69.
GuptaA, MishraSK. A novel analytical method for simultaneous quantification of silodosin and tadalafil by RP-HPLC. Jpri, 2021; 33(39B):193–202. https://doi.org/10.9734/jpri/2021/v33i39B32195
70.
ErE, ErkN. An effective and sensitive stability indicating chromatographic approach based on HPLC for silodosin assay. J Anal Sci Technol, 2016; 7:20. doi: 10.1186/s40543-016-0100-y
71.
OmarMA, MohamedAM, DerayeaI, et al.Selective spectrofluorimetric method with enhanced sensitivity for determination of silodosin in dosage form and human plasma application to stability studies and content uniformity testing. J Fluoresc, 2017; 27(2):473–482.
72.
EssamHM, El RefayeMS, El-SharawyDM. Radiolabelling and biological assessment of 99mTc-Mebeverine as a possible tracer for solid tumor diagnosis. Egypt J RadSci, 2021; 0(0):0–0.
73.
SanadMH, EyssaHM, MarzookFA, et al.Radioiodinated Procainamide as Radiotracer for Myocardial Perfusion Imaging in Mice. Pharmaceutical Chemistry Journal, 2023; 57(5):543–549; doi: 10.1007/s11094-023-02918-w
74.
MahmoudAF, AboumaneiMH, Hamada Abd-AllahW, et al.New frontier radioiodinated probe based on in silico resveratrol repositioning for microtubules dynamic targeting. Int J Radiat Biol, 2023; 99(2):281–291; doi: 10.1080/09553002.2022.2078001
75.
BancroftJD, StevensA, TurnerDR. Theory and Practice of Histological Techniques. 4th Edn., Churchill, Livingston, New York, London, San Francisco, Tokyo. 2013.
76.
JonesRT. Histological examination of prostate tissue: A comprehensive guide. Journal of Histopathology and Case Reports, 2019; 7(2):123–132.
77.
De VitaVT, LawrenceTS, RosenbergSA. eds. Prostate and Other Genitourinary Cancers: Cancer: Principles and Practice of Oncology. Wolters Kluwer Health.18 March 2016;1006. ISBN 978-1-4963-5421-1.
78.
SmithJA. Prostate cancer induction and marker analysis in mice. Journal of Experimental Medicine, 2022; 129(3):1234–1245.
79.
El HilaliN, RubioN, VillacampaM, et al.Combined noninvasive imaging and luminometric quantification of luciferase labeled human prostate tumors and metastases. Lab Invest, 2002; 82(11):1563–1571.
80.
JiangZK, SatoM, WeiLH, et al.Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res, 2011; 71(19):6250–6260.
81.
PolizioAH, PeñaC. Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept, 2005; 128(1):1–5.
82.
Ray BanerjeeS, PullambhatlaM, FossCA, et al.Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem, 2013; 56(15):6108–6121.
83.
ShakurA, HamesK, O’SheaA, et al.“Prostatitis: Imaging appearances and diagnostic considerations. Clin Radiol, 2021; 76(6):416–426.
84.
NagelKNA, SchoutenMG, HambrockT, et al.“Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology, 2013; 267(1):164–172.
85.
ChappleCR, MontorsiF, TammelaTLJ, et al.; European Silodosin Study Group. “Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. Eur Urol, 2011; 59(3):342–352.
86.
CantrellMA, Bream-RouwenhorstHR, HemersonP, et al.New drug approvals: Silodosin for benign prostatic hyperplasia. Ann Pharmacother, 2010; 44(2):302–310.
87.
KawabeK, YoshidaM, HommaY, et al.; Silodosin Clinical Study Group. “Silodosin, a new α1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men. BJU Int, 2006; 98(5):1019–1024.
88.
RobuS, SchotteliusM, EiberM, et al.Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med, 2017; 58(2):235–242.
89.
AebiH. Catalase, in: Methods of enzymatic analysis (BergrenyerH. U. Ed.). Academic Press, New York, 1974; 673–684.
90.
MisuraHP, FridovichI. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem, 1972; 247:3170–3175.
91.
PaulisG. Inflammatory mechanisms and oxidative stress in prostatitis: The possible role of antioxidant therapy. Res Rep Urol, 2018; 10:75–87; doi: 10.2147/RRU.S170400
92.
MeagherEA, FitzGeraldGA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med, 2000; 28(12):1745–1750; doi: 10.1016/s0891-5849(00)00232-x
93.
MerendinoRA, SalvoF, SaijaA, et al.Malondialdehyde in benign prostate hypertrophy: A useful marker? Mediators Inflamm, 2003; 12(2):127–128; doi: 10.1080/0962935031000097745
94.
OlinskiR, ZastawnyTH, FoksinskiM, et al.DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic Biol Med, 1995; 18(4):807–813; doi: 10.1016/0891-5849(94)00171-f
95.
PaceG, Di MassimoC, De AmicisD, et al.Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int, 2010; 85(3):328–333; doi: 10.1159/00031506438
96.
Ub WijerathneC, ParkH-S, JeongH-Y, et al.Quisqualisindica improves benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis. Biol Pharm Bull, 2017; 40(12):2125–2133; doi: 10.1248/bpb.b17-00468
97.
ParkHS, SeoCS, WijerathneCU, et al.Effect of veratrummaackii on testosterone propionate-induced benign prostatic hyperplasia in rats. Biol Pharm Bull, 2019; 42(1):1–9; doi: 10.1248/bpb.b18-0031
98.
SfanosKS, De MarzoAM. Prostate cancer and inflammation: The evidence. Histopathology, 2012; 60(1):199–215.
99.
NiaziAB, AsifM, AhmadI, et al.Therapeutic potential of silodosin for chronic prostatitis: Efficacy and safety insights. Pakistan Journal of Health Sciences, 2024; 5(7):147–151; doi: 10.5439/3/pjhs.v5i07.1883
100.
BracardaS, de CobelliO, GrecoC, et al.Cancer of the prostate. Critical reviews in oncology/hematology. Crit Rev Oncol Hematol, 2005; 56(3):379–396.
101.
De NunzioC, KramerG, MarbergerM, et al.The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol, 2011; 60(1):106–117.
102.
HayesJH, BarryMJ. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA, 2014; 311(11):1143–1149.
103.
NorströmMM, RådestadE, SundbergB, et al.Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget, 2016; 7(17):23581–23593.
104.
VillaL, CapogrossoP, CapitanioU, et al.Silodosin: An update on efficacy, safety and clinical indications in urology. Adv Ther, 2019; 36(1):1–18.
105.
SchilitS, BenzeroualKE. Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther, 2009; 31(11):2489–2502.
106.
ManovJJ, MohanPP, KavaB, et al.“Benign prostatic hyperplasia: A brief overview of pathogenesis, diagnosis, and current state of therapy. Techniques in Vascular and Interventional Radiology , 2020; 23(3):100687.
107.
VickmanRE, FrancoOE, MolineDC, et al.The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J Urol, 2020; 7(3):191–202.
108.
LloydGL, Marks and JM, RickeWA. “Benign prostatic hyperplasia and lower urinary tract symptoms: What is the role and significance of inflammation? Curr Urol Rep, 2019 ;20(9):54–58.
